ABL1 / 2 (Ab 393 / 429) Antilichaam

Regulates cytoskeleton remodeling during cell differentiation, cell division and cell adhesion. Localizes to dynamic actin structures, and phosphorylates CRK and CRKL, DOK1, and other proteins controlling cytoskeleton dynamics. Regulates DNA repair potentially by activating the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks.

25;27

P00519P42684

NP_005148.2; NP_001129472.1

Human, Mouse

ABL1/2 (Ab-393/429) antibody was raised against a peptide sequence around aa.391~395/427~431 (D-T-Y-T-A) derived from ABL1/2 .

Unconjugated

Primary Antibodies

Cell Cycle

Antibodies were purified by affinity-chromatography using epitope-specific peptide.

1 mg/mL

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

None

Blue Ice

Store antibody at -20˚ C for up to one year.

135, 210 kDa

This antibody detects endogenous levels of total ABL1/2 protein.

Western Blot: 1:500~1:1000

ABL1 ABL2

C-abl oncogene 1, non-receptor tyrosine kinase / c-abl oncogene 2, non-receptor tyrosine kinase

This antibody was raised against a peptide sequence around aa.391~395/427~431 (D-T-Y-T-A) derived from ABL1/2

Wang, J. Y. et al. (2000) Oncogene 19, 5643-5650. Danial, N. N. et al. (2000) Oncogene 19, 2523-2531. Brasher, B. B. et al. (2000) J. Biol. Chem. 275, 35631-35637. Pluk, H. et al. (2002) Cell 108, 247-259.

ABL, JTK7, p150, c-ABL, v-abl, c-ABL1, bcr/abl, MAPKAPK1A, RSK1, ABL

WB

62362414 / 209862772

Liquid